Medicines

Here you will find the recommendations we have made about the use of individual medicines in Lancashire.

Infliximab

Brand: Remicade┬«, Inflectra┬«, Remsima┬«
NICE TA: 187
Indication: Crohn's disease, 2nd line biologic (NICE TA187) and LMMG Recommendation
Disease category: 
Commissioning responsibility: CCG
PbR excluded: Yes

Background

In CD patients who experience intolerance, secondary failure or primary failure with a first TNF-alpha inhibitor used in line with NICE, treatment with a second NICE TA187-approved TNF-alpha inhibitor may be tried. There is consistent evidence that a second TNF-alpha inhibitor can induce and maintain clinical response and remission in many patients who experience inadequate control or intolerance on their first TNF-alpha inhibitor. Response and remission rates with a second TNF-alpha inhibitor are highest in those who discontinue their first TNF-alpha inhibitor due to intolerance or loss of response, compared with those who discontinue due to lack of an adequate initial response.

Decisions of Lancashire local decision making groups:

NHS Blackburn With Darwen CCG and NHS East Lancashire CCG NHS Blackpool CCG NHS Chorley and South Ribble CCG and NHS Greater Preston CCG NHS Fylde and Wyre CCG NHS Morecambe Bay CCG NHS West Lancashire CCG

Red

Red

Red

Red

Red

Red